Caixin Li

Diady Biotechnology (Shanghai) Co., Ltd., Shanghai, 201100, China
Author    Correspondence author
International Journal of Molecular Medical Science, 2024, Vol. 14, No. 2   
Received: 04 Apr., 2024    Accepted: 07 May, 2024    Published: 15 May, 2024

This is an open access article published under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Mesenchymal stem cells (MSCs) have become a research focus in the treatment of autoimmune diseases due to their unique immunomodulatory function and multidirectional differentiation potential. MSCs can effectively regulate inflammatory response and immune balance by secreting anti-inflammatory and immune regulatory factors and directly interacting with immune cells. This study reviews the application, challenges, and future research directions of MSCs in the treatment of autoimmune diseases. Studies have shown that MSCs have shown potential therapeutic efficacy in clinical trials for diseases such as systemic lupus erythematosus, rheumatoid arthritis and Crohn's disease, reducing symptoms and improving patients' quality of life. However, its clinical application still faces dual challenges of safety and efficacy, including inconsistencies in cell source and preparation process, long-term survival and transformation risks. Future research should focus on optimizing the production and application processes of MSCs, exploring ways to enhance their immunomodulatory effects through genetic engineering and bioengineering techniques, and verifying their safety and efficacy through large-scale clinical trials. Through continued research and technological innovation, MSCs are expected to provide an effective new strategy for the treatment of autoimmune diseases.

Mesenchymal stem cells (MSCs); Autoimmune diseases; Immunomodulation; Multi-directional differentiation; Clinical trials